SRPT logo

Sarepta Therapeutics, Inc.

SRPT
Healthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30

Analyst Consensus

Buy55 analysts
Strong Buy
0
Buy
31
Hold
18
Sell
6
Strong Sell
0
Consensus Target
$21.00
Implied Upside
+17.8%
Low Target
$17.00
High Target
$27.00

Price Target Trend

Last Month
$18.00
1 target · +1% vs price
Last Quarter
$17.50
2 targets · -2% vs price
Last Year
$23.93
14 targets · +34% vs price
All Time
$108.08
72 targets · +507% vs price

Rating Trend

Dec 25
7 buy · 14 hold · 5 sell
Jan 26
7 buy · 14 hold · 5 sell
Feb 26
7 buy · 14 hold · 5 sell
Mar 26
7 buy · 13 hold · 5 sell
Apr 26
8 buy · 13 hold · 5 sell
May 26
8 buy · 13 hold · 5 sell
Jun 26
7 buy · 13 hold · 5 sell
Jul 26
8 buy · 13 hold · 5 sell
Aug 26
8 buy · 11 hold · 5 sell
Sep 26
8 buy · 12 hold · 5 sell
Oct 26
7 buy · 12 hold · 5 sell
Nov 26
7 buy · 12 hold · 5 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 6, 2026Robert W. BairdBrian Skorney$18.00(+2%)$17.57StreetInsider
Oct 8, 2026RBC Capital$17.00(-2%)$17.43TheFly
Jul 27, 2026Morgan Stanley$25.00(+54%)$16.28TheFly
Jul 9, 2026Piper Sandler$20.00(-1%)$20.21TheFly
Jul 8, 2026Wolfe Research$27.00(+34%)$20.21TheFly
May 15, 2026Evercore ISI$19.00(+4%)$18.20TheFly
Mar 26, 2026Deutsche Bank$14.00(-35%)$21.68TheFly
Mar 26, 2026Wedbush$35.00(+61%)$21.68TheFly
Mar 12, 2026Mizuho SecuritiesUy Ear$31.00(+82%)$17.04StreetInsider
Mar 3, 2026Loop Capital MarketsIlya Zubkov$25.00(+58%)$15.87StreetInsider
Mar 3, 2026JefferiesAndrew Tsai$30.00(+88%)$15.98StreetInsider
Jan 27, 2026Robert W. Baird$22.00(-4%)$22.80TheFly
Dec 9, 2025Wedbush$32.00(+46%)$21.86TheFly
Nov 25, 2025Bernstein$20.00(+6%)$18.91TheFly
Nov 5, 2025Barclays$20.00(+23%)$16.20TheFly
Nov 5, 2025Mizuho SecuritiesUy Ear$26.00(+60%)$16.20StreetInsider
Nov 4, 2025Robert W. BairdBrian Skorney$15.00(-39%)$24.45StreetInsider
Oct 30, 2025Piper SandlerBiren Amin$16.00(-32%)$23.45TheFly
Sep 9, 2025Leerink PartnersJoseph Schwartz$15.00(-15%)$17.57TheFly
Aug 21, 2025Barclays$22.00(+10%)$20.06TheFly

Recent Rating Actions

FirmActionRatingDate
RBC CapitalmaintainSector PerformNov 6, 2026
RBC CapitalmaintainSector PerformOct 8, 2026
HC Wainwright & Co.maintainSellOct 5, 2026
JP MorganmaintainNeutralSep 30, 2026
NeedhammaintainUnderperformSep 28, 2026
Wolfe ResearchupgradePeer Perform →OutperformJul 9, 2026
Piper SandlermaintainNeutralJul 9, 2026
HC Wainwright & Co.maintainSellApr 16, 2026
CitigroupmaintainSellMar 26, 2026
NeedhammaintainUnderperformMar 26, 2026
OppenheimermaintainOutperformMar 19, 2026
MizuhomaintainOutperformMar 13, 2026
CitigroupmaintainSellMar 10, 2026
HC Wainwright & Co.maintainSellMar 2, 2026
Wells FargomaintainOverweightFeb 27, 2026
HC Wainwright & Co.maintainSellJan 27, 2026
WedbushmaintainOutperformJan 23, 2026
HC Wainwright & Co.maintainSellJan 14, 2026
GuggenheimmaintainBuyNov 5, 2025
BarclaysmaintainEqual WeightNov 5, 2025
Wells FargomaintainOverweightNov 5, 2025
MizuhoupgradeNeutral →OutperformNov 5, 2025
BairdmaintainNeutralNov 4, 2025
Piper SandlermaintainNeutralOct 30, 2025
BMO CapitalupgradeMarket Perform →OutperformSep 22, 2025

Earnings History

Next report: Feb 24, 2027 · EPS est. $-0.06
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 5, 2026$0.13$0.07$381.4M$352.2M
Aug 5, 2026$-0.05$0.22$401.3M$366.4M
May 6, 2026$3.16$0.98$730.8M$474.2M
Feb 25, 2026$-3.58$-1.03$442.9M$369.6M
Nov 3, 2025$-1.80$-0.73$399.4M$335.8M
Aug 6, 2025$2.02$0.83$611.1M$530.7M
May 6, 2025$-4.60$-0.87$744.9M$687.5M
Feb 26, 2025$1.50$1.38$658.4M$631.0M

News

Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Officer Conference Call Participants Adhiraj Chauhan - JPMorgan Chase &…

Nov 7, 2026seekingalpha.com
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.

Nov 6, 2026zacks.com
Sarepta Therapeutics Q3 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.

Nov 6, 2026marketbeat.com
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Nov 5, 2026zacks.com
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opport.

Nov 5, 2026businesswire.com
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oct 29, 2026zacks.com
Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in…

Oct 26, 2026businesswire.com
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations.

Oct 22, 2026businesswire.com
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)

Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Profitability This table compares Protagonist Therapeutics and Sarepta

Oct 19, 2026defenseworld.net
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (DM1), can directly reduce pathogenic DMPK transcripts within the nucleus, where the molecular drivers o.

Oct 14, 2026businesswire.com
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.

Oct 6, 2026benzinga.com
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A.

Oct 5, 2026businesswire.com
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC Wainwright in a research report issued on Monday, MarketBeat.com reports. They currently have a $5.00 target price on the biotechnology company's stock. HC Wainwright's target price points to a potential downside of 71.43% from the stock's previous close. A number

Oct 5, 2026defenseworld.net
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.

Sep 30, 2026businesswire.com
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy. In ambulatory patients treated at ages 8 to 12, an age range in which functional decline becomes even m.

Sep 30, 2026businesswire.com
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta'.

Sep 25, 2026businesswire.com
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvov.

Sep 24, 2026businesswire.com
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,026 shares of the biotechnology company's stock after selling 48,276 shares during the

Sep 16, 2026defenseworld.net
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.

Sep 15, 2026marketbeat.com
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 14, 2026seekingalpha.com